DR-454 The genomic landscapes of MLH1-mutated and/or CTNNB1-mutated colorectal carcinomas

No Featured Image set

Colorectal cancer (CRC) is a heterogeneous disease comprising subtypes with distinct clinical and/or molecular characteristics. Roughly, two major categories of sporadic CRCs are discerned i.e. ‘classical’ chromosomal instable (85%) and microsatellite-instable (MSI) CRCs (15%), the latter being characterized by erroneous replication of nucleotide-repeat sequences and significantly higher mutation frequencies than classical CRCs and therefore  also denoted as hypermutated CRCs. In the vast majority of CRCs, the Wnt route is constitutively active due to deletion of and/or loss-of-function mutations in the APC gene. In 1-5% of all sporadic CRCs however the Wnt pathway is unleashed by activating CTNNB1 mutations. 

We studied MSI CRCs lacking MLH1 and PMS2 expression as due to bi-allelic inactivating MLH1 gene mutations, either somatic or in germline. Interestingly, we found that in 60% of sporadic and 40% of MLH1-Lynch-associated MSI CRCs the WNT pathway is driven by activating CTNNB1 mutations instead of APC mutations.  Based on these findings, we define a subgroup of MSI CRCs potentially derived of yet unidentified precursor lesions.

Carel Van Noesel, Amsterdam UMC, the Netherlands

Terug naar nieuws

Meer nieuws

Koos van der Hoeven nieuw directielid Hartwig Medical Foundation

Koos van der Hoeven nieuw directielid Hartwig Medical Foundation

10-01-2020

Met ingang van 1 januari 2020 is prof. dr. ir. J.J.M. (Koos) van der Hoeven (‘52) benoemd tot derde directielid …

DNA-diagnostiek wordt steeds meer mainstream

DNA-diagnostiek wordt steeds meer mainstream

04-04-2019

19 april 2019 Prof. dr. Eveline Bleiker ziet de vraag naar DNA-diagnostiek in de oncologische zorg toenemen. “De uitslag is …

Groeifonds investeert 325 miljoen euro in Oncode-PACT om ontwikkeling kankermedicijnen te versnellen

Groeifonds investeert 325 miljoen euro in Oncode-PACT om ontwikkeling kankermedicijnen te versnellen

14-04-2022

Het Nationaal Groeifonds investeert in totaal 325 miljoen euro in het plan van Oncode-PACT om het preklinische ontwikkelproces van kankermedicijnen …

Wilt u op de hoogte blijven van nieuwe ontwikkelingen?

Abonneer u op onze nieuwsbrieven

Meer weten over de complete DNA-test?

Ga naar OncoAct.nl